RenovoRx Inc (RNXT)
1.37
+0.07
(+5.38%)
USD |
NASDAQ |
May 08, 16:00
RenovoRx Cash from Financing (TTM): 5.008M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 5.008M |
| September 30, 2023 | 5.011M |
| June 30, 2023 | 5.015M |
| March 31, 2023 | 0.022M |
| December 31, 2022 | 0.042M |
| September 30, 2022 | 0.064M |
| June 30, 2022 | 17.35M |
| Date | Value |
|---|---|
| March 31, 2022 | 19.32M |
| December 31, 2021 | 19.33M |
| September 30, 2021 | 19.76M |
| June 30, 2021 | 2.469M |
| March 31, 2021 | 1.921M |
| December 31, 2020 | 3.199M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.022M
Minimum
Mar 2023
19.76M
Maximum
Sep 2021
7.577M
Average
5.008M
Median
Dec 2023
Cash from Financing (TTM) Benchmarks
| Annexon Inc | 135.52M |
| Longeveron Inc | 5.262M |
| MiNK Therapeutics Inc | -0.4072M |
| Adlai Nortye Ltd | 9.238M |
| Telomir Pharmaceuticals Inc | -- |